Skin Autofluorescence-Indicated Advanced Glycation End Products as Predictors of Cardiovascular and All-Cause Mortality in High-Risk Subjects: A Systematic Review and Meta-analysis. Cavero-Redondo, I., Soriano-Cano, A., Álvarez-Bueno, C., Cunha, P. G., Martínez-Hortelano, J. A., Garrido-Miguel, M., Berlanga-Macías, C., & Martínez-Vizcaíno, V. Journal of the American Heart Association, 7(18):e009833, September, 2018.
doi  abstract   bibtex   
Background Chronic deposits of advanced glycation end products produced by enzymatic glycation have been suggested as predictors of atherosclerotic-related disorders. This study aimed to estimate the relationship between advanced glycation end products indicated by skin autofluorescence levels and the risk of cardiovascular and all-cause mortality based on data from observational studies. Methods and Results We systematically searched Medline, Embase, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and the Web of Science databases from their inceptions until November 2017 for observational studies addressing the association of advanced glycation end products by skin autofluorescence levels with cardiovascular and all-cause mortality. The DerSimonian and Laird random-effects method was used to compute pooled estimates of hazard ratios and their respective 95% confidence intervals for the risk of cardiovascular and all-cause mortality associated with levels of advanced glycation end products by skin autofluorescence. Ten published studies were included in the systematic review and meta-analysis. Higher skin autofluorescence levels were significantly associated with a higher pooled risk estimate for cardiovascular mortality (hazard ratio: 2.06; 95% confidence interval, 1.58-2.67), which might not be important to moderate heterogeneity (I2=34.7%; P=0.163), and for all-cause mortality (hazard ratio: 1.91; 95% confidence interval, 1.42-2.56) with substantial heterogeneity (I2=60.8%; P=0.0.18). Conclusions Our data suggest that skin autofluorescence levels could be considered predictors of all-cause mortality and cardiovascular mortality in patients at high and very high risk.
@article{cavero-redondo_skin_2018,
	title = {Skin {Autofluorescence}-{Indicated} {Advanced} {Glycation} {End} {Products} as {Predictors} of {Cardiovascular} and {All}-{Cause} {Mortality} in {High}-{Risk} {Subjects}: {A} {Systematic} {Review} and {Meta}-analysis},
	volume = {7},
	issn = {2047-9980},
	shorttitle = {Skin {Autofluorescence}-{Indicated} {Advanced} {Glycation} {End} {Products} as {Predictors} of {Cardiovascular} and {All}-{Cause} {Mortality} in {High}-{Risk} {Subjects}},
	doi = {10.1161/JAHA.118.009833},
	abstract = {Background Chronic deposits of advanced glycation end products produced by enzymatic glycation have been suggested as predictors of atherosclerotic-related disorders. This study aimed to estimate the relationship between advanced glycation end products indicated by skin autofluorescence levels and the risk of cardiovascular and all-cause mortality based on data from observational studies. Methods and Results We systematically searched Medline, Embase, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and the Web of Science databases from their inceptions until November 2017 for observational studies addressing the association of advanced glycation end products by skin autofluorescence levels with cardiovascular and all-cause mortality. The DerSimonian and Laird random-effects method was used to compute pooled estimates of hazard ratios and their respective 95\% confidence intervals for the risk of cardiovascular and all-cause mortality associated with levels of advanced glycation end products by skin autofluorescence. Ten published studies were included in the systematic review and meta-analysis. Higher skin autofluorescence levels were significantly associated with a higher pooled risk estimate for cardiovascular mortality (hazard ratio: 2.06; 95\% confidence interval, 1.58-2.67), which might not be important to moderate heterogeneity (I2=34.7\%; P=0.163), and for all-cause mortality (hazard ratio: 1.91; 95\% confidence interval, 1.42-2.56) with substantial heterogeneity (I2=60.8\%; P=0.0.18). Conclusions Our data suggest that skin autofluorescence levels could be considered predictors of all-cause mortality and cardiovascular mortality in patients at high and very high risk.},
	language = {eng},
	number = {18},
	journal = {Journal of the American Heart Association},
	author = {Cavero-Redondo, Ivan and Soriano-Cano, Alba and Álvarez-Bueno, Celia and Cunha, Pedro G. and Martínez-Hortelano, Jose A. and Garrido-Miguel, Miriam and Berlanga-Macías, Carlos and Martínez-Vizcaíno, Vicente},
	month = sep,
	year = {2018},
	pmid = {30371199},
	pmcid = {PMC6222966},
	keywords = {AGE Reader in CVD, AGE Reader in high CV risk patients, Biomarkers, Cardiovascular Diseases, Cause of Death, Global Health, Glycation End Products, Advanced, Humans, Incidence, Key Publications, Luminescent Measurements, Predictive Value of Tests, Risk Assessment, Risk Factors, Skin, Survival Rate, advanced glycation end products, cardiovascular complications, meta‐analysis, mortality, skin autofluorescence},
	pages = {e009833},
}

Downloads: 0